Does Infliximab Dyyb Interact with Abatacept?
CDI records a contraindicated classification for Infliximab Dyyb and Abatacept. The stored summary is: Combination with abatacept is not recommended due to increased risk of serious infections with no added clinical benefit seen in clinical studies of TNF blockers. The mechanism involves increased immunosuppression leading to serious infections. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Infliximab Dyyb Class
- Tumor Necrosis Factor Blocker
- Abatacept Class
- Selective T Cell Costimulation Modulator
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Increased immunosuppression leading to serious infections
What To Tell Your Doctor or Pharmacist
If you are taking Infliximab Dyyb and your doctor is considering prescribing Abatacept (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider